TrialInflammatory bowel diseases2025

Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.

Stefan Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.